Genostics® partners with world-class cancer research laboratories in Europe to bring the very best in personalised cancer testing to the Australian and New Zealand medical communities.
We engage with pioneering practitioners who seek to discover the exact nature of each patient's cancer. These practitioners use Genostics® tests to help design personalised treatment plans and to closely monitor the effectiveness of therapies.
Specialising in the field of Oncology, we are proud to be bringing the future of personalised cancer testing to patients, today.
June 30, 2015
Detecting the rare, renegade cancer cells ...Learn more
June 18, 2015
Survival of the fittest in cancer ...Quick read of this blog
June 8, 2015
"Even if surgery, chemotherapy, or radiation removes all traces of known cancer, there is still a risk of the cancer returning, often in a distant location in the body. This may occur as a result of CTCs."
...Read the article
June 2, 2015
Which chemotherapy kills the cells responsible for cancer spread, doctor?
May 18, 2015
Gene expression and the regulation of genes
...Read this article
May 11, 2015
Genetics, explained simply
...Read this blog post
May 5, 2015
What is a biomarker, and how are CTCs defined as both a biomarkers and carriers of biomarkers? ...Learn more
April 27, 2015
Circulating Tumour Cells: tell me more ...Read this article
April 20, 2014
How cancer spreads: the biology of metastasis ...Quick view
April 13 2015
DNA, Cancer, and what it takes for a cell to become cancerous ...Read this blog post
We are very excited to announce the launch of the world's first Circulating Tumour Cell blog, written specifically for practitioners and their patients.
Dr. Fluhrer gives NewYou an in-depth look at the
intertwined world of cancer testing and molecular medicine.
"In what specific ways can personalised cancer testing and molecular medicine revolutionise the way people treat and think of cancer?
Every person is a separate individual, similarly every cancer is also ‘individual’ to the person affected, in a manner of speaking; cancer is heterogeneous. Cells in a malignant tumour can include cancer stem cells, promoter cells, communication cells, supportive cells, immune cells etc. Some of the cancer cells produce proteins that inhibit the immune system to recognise them and kill it." ...Read the rest of this article
'Best of the best' publication
Prof. Pachmann's poster, outlining the use of Maintrac® technology in uncovering the heterogenous nature of Circulating Tumour Cells, was awarded 'The best of the best' poster at the Clinical Oncology Society of Australia conference. Somatic mutations of the EGFR, KRAS and BRAF genes: homogeneitiy in single cells from cell lines and heterogeneity in Circulating Epithelial Tumor Cells (CETCs) as determined using cobas® z480 analyzer (2014) ...Quick view
A growing tumour is made up of many different cancer cells. If a cancer is malignant, a select population of cancer cells can escape the tumour mass and invade the blood stream. When this happens, the cancer is at a turning point. Escapee cancer cells in the blood stream can travel to another site in the body and grow a second tumour at a later stage, called a metastasis. These escapee cancer cells in the blood are called Circulating Tumour Cells, abbreviated as ‘CTCs.’
"There is increasing evidence that CTCs reflect cancer progression in real time and that this information may be particularly helpful in the context of systemic therapies. In the future, CTC characterisation is expected to contribute to guiding specific targeted therapies to a defined population of cancer patients within a certain therapeutic window...